0 518

Cited 13 times in

Prognostic Value of FDG Uptake of Portal Vein Tumor Thrombosis in Patients With Locally Advanced Hepatocellular Carcinoma

DC Field Value Language
dc.contributor.author김도영-
dc.contributor.author윤미진-
dc.contributor.author한광협-
dc.contributor.author황상현-
dc.date.accessioned2018-07-20T08:04:01Z-
dc.date.available2018-07-20T08:04:01Z-
dc.date.issued2017-
dc.identifier.issn0363-9762-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/160808-
dc.description.abstractPURPOSE: This study aimed to evaluate the prognostic value of F-FDG uptake of portal vein tumor thrombosis (PVTT) for predicting progression-free survival (PFS) and overall survival (OS) in patients with locally advanced hepatocellular carcinoma (HCC). METHODS: The study retrospectively included 166 HCC patients with PVTT and no extrahepatic metastases who underwent staging FDG PET/CT. Tumor-to-liver uptake ratio (TLR) and PVTT-to-liver uptake ratio (PLR) were measured for each patient, and the prognostic values of clinical factors, TLR, and PLR were assessed. Furthermore, patients were classified into 2 subgroups according to TLR, and the prognostic value of PLR was evaluated in each subgroup. RESULTS: Median PFS and OS were 6.2 and 10.1 months, respectively. On multivariate analysis, tumor size (P = 0.006) and PLR (P = 0.03) were independent prognostic factors for PFS, whereas Child-Pugh class (P = 0.02) and PLR (P = 0.02) were independent prognostic factors for OS. Tumor-to-liver uptake ratio was a significant prognostic factor for PFS and OS on univariate analysis but failed to show significance on multivariate analysis. In both patient subgroups with low and high TLR, PLR remained a significant prognostic factor for predicting OS (P = 0.04 for all). CONCLUSIONS: FDG uptake of PVTT, but not FDG uptake of HCC, is an independent prognostic factor for PFS and OS in HCC patients with PVTT and no extrahepatic metastasis. Given the prognostic significance, it is strongly encouraged to use FDG uptake of PVTT in further risk stratification for HCC patients with PVTT.-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherLippincott-
dc.relation.isPartOfCLINICAL NUCLEAR MEDICINE-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAged, 80 and over-
dc.subject.MESHAntineoplastic Agents/therapeutic use-
dc.subject.MESHCarcinoma, Hepatocellular/complications-
dc.subject.MESHCarcinoma, Hepatocellular/diagnostic imaging*-
dc.subject.MESHCarcinoma, Hepatocellular/therapy-
dc.subject.MESHChemoembolization, Therapeutic/methods-
dc.subject.MESHChemoradiotherapy/methods-
dc.subject.MESHDisease-Free Survival-
dc.subject.MESHFemale-
dc.subject.MESHFluorodeoxyglucose F18-
dc.subject.MESHHumans-
dc.subject.MESHInfusions, Intra-Arterial-
dc.subject.MESHLiver Neoplasms/complications-
dc.subject.MESHLiver Neoplasms/diagnostic imaging*-
dc.subject.MESHLiver Neoplasms/therapy-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHPortal Vein/diagnostic imaging*-
dc.subject.MESHPositron Emission Tomography Computed Tomography-
dc.subject.MESHPrognosis-
dc.subject.MESHRadiopharmaceuticals-
dc.subject.MESHRetrospective Studies-
dc.subject.MESHVenous Thrombosis/diagnostic imaging*-
dc.subject.MESHVenous Thrombosis/etiology-
dc.titlePrognostic Value of FDG Uptake of Portal Vein Tumor Thrombosis in Patients With Locally Advanced Hepatocellular Carcinoma-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine-
dc.contributor.departmentDept. of Internal Medicine-
dc.contributor.googleauthorLee, Jeong Won-
dc.contributor.googleauthorHwang, Sang Hyun-
dc.contributor.googleauthorKim, Do Young-
dc.contributor.googleauthorHan, Kwang-Hyub-
dc.contributor.googleauthorYun, Mijin-
dc.identifier.doi10.1097/RLU.0000000000001422-
dc.contributor.localIdA00385-
dc.contributor.localIdA02550-
dc.contributor.localIdA04268-
dc.relation.journalcodeJ00595-
dc.identifier.eissn1536-0229-
dc.identifier.pmid27775940-
dc.identifier.urlhttp://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&AN=00003072-201701000-00030&LSLINK=80&D=ovft-
dc.contributor.alternativeNameKim, Do Young-
dc.contributor.alternativeNameYun, Mi Jin-
dc.contributor.alternativeNameHan, Kwang Hyup-
dc.contributor.affiliatedAuthorKim, Do Young-
dc.contributor.affiliatedAuthorYun, Mi Jin-
dc.contributor.affiliatedAuthorHan, Kwang Hyup-
dc.citation.volume42-
dc.citation.number1-
dc.citation.startPagee35-
dc.citation.endPagee40-
dc.identifier.bibliographicCitationCLINICAL NUCLEAR MEDICINE, Vol.42(1) : e35-e40, 2017-
dc.identifier.rimsid60692-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Nuclear Medicine (핵의학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.